|Videos|January 17, 2023
Review of Clinical Trial Data Investigating the Treatment of Advanced RAI-R-DTC
Author(s)Lori J. Wirth, MD
Dr Lori Wirth discusses the design and data of two key clinical trials that led to the approval of the current treatment options for patients with advanced RAI-R-DTC.
Advertisement
Episodes in this series
Advertisement
Related to this article
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
The phase 2/3 AHEAD-MERIT trial will continue to evaluate patients with HPV-positive head and neck squamous cell carcinoma for its second primary end point of overall survival.
Advertisement
Advertisement